Explore the evolution of Pharma CDMOs in India and the rise of the CDMO 2.0 model in 2026. Discover key trends, market growth, biologics, digital transformation, and why India is emerging as a global hub for contract development and manufacturing.
ZEISS India has launched its new ClearMind lenses today, bringing a fresh approach to everyday vision. The ClearMind lenses are designed to deliver sharper clarity while reducing the cognitive load caused by blurry vision, making them ideal for...
Takeda Pharmaceutical Company is a step closer to dengue vaccine Import approval in India after receiving a positive recommendation from the Subject Expert Committee, marking a major development in the country’s fight against mosquito-borne diseases.
Novo Nordisk is set to cut the Ozempic price in India as Indian generics flood the market following the patent expiry.
India’s pharmaceutical industry is grappling with a severe raw material crisis, putting immense pressure on API producers. Prices of key chemicals and Active Pharmaceutical Ingredients (APIs) have skyrocketed, forcing manufacturers to cut production
Alkem Laboratories has announced the launch of its semaglutide injection in India, introducing a more affordable option for patients managing type 2 diabetes and weight issues.
In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Vikas Bansi, Business Director - Healthcare, Himalaya Wellness Company, discusses how pharmaceutical companies are navigating the growing demand for OTC
India’s drug ingredient makers are facing a sharp rising chemical costs crisis, as surging prices of key inputs disrupt production and squeeze margins across the pharmaceutical supply chain.
The painkiller and antibiotic prices in India are set to rise slightly from April 1, following an annual revision linked to inflation.
India and Japan have signed a major agreement to invest JPY 275 billion in Maharashtra healthcare system, marking a significant step toward improving public health infrastructure in the state.